At its Pharma Day, Swiss pharmaceutical giant Roche Holdings AG (OTC:RHHBY) outlined five priority therapeutic areas: neurology, oncology and hematology, immunology, ophthalmology, and cardiovascular, ...

Roche targets liver disease treatments with acquisition Deal includes $14.50 a share, potential milestone payments up to $6.00 a share Roche flags potential to treat obesity-related conditions The ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

The move aims to transform the nation into a strategic centre for global clinical trials and biotechnology innovation in Asia ...

LONDON, Sept 22 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab signalled its ambition to join Eli Lilly and Novo Nordisk at the top of the booming weight-loss market on Monday, as it ...

Major drugmakers Roche, AstraZeneca, and Johnson & Johnson plan to invest billions to expand drug manufacturing in the United States.

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...

Charles R. Goulding and Aaron Rofe... reveal how overlooked incentives can quietly turn everyday operations into major savings.